- Home
- VOR vs RNAC Comparison
VOR vs RNAC Comparison
Compare VOR & RNAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VOR | RNAC |
|---|---|---|
| Founded | 2015 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 562.6M | 217.1M |
| IPO Year | 2021 | 2016 |
Fundamental Metrics
Financial Performance| Metric | VOR | RNAC |
|---|---|---|
| Price | $15.19 | $7.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 5 |
| Target Price | ★ $64.78 | $38.80 |
| AVG Volume (30 Days) | ★ 696.6K | 117.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2.86 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $38,913,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 49.64 |
| 52 Week Low | $0.13 | $5.98 |
| 52 Week High | $49.95 | $18.80 |
Technical Indicators
Market Signals| Indicator | VOR | RNAC |
|---|---|---|
| Relative Strength Index (RSI) | 55.43 | 53.40 |
| Support Level | $11.27 | $7.06 |
| Resistance Level | $16.80 | $7.99 |
| Average True Range (ATR) | 1.16 | 0.60 |
| MACD | 0.23 | 0.12 |
| Stochastic Oscillator | 57.95 | 56.38 |
Price Performance
Historical ComparisonAbout VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
About RNAC Cartesian Therapeutics Inc.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.